Identifying incipient dementia individuals using machine learning and amyloid imaging.

Citation data:

Neurobiology of aging, ISSN: 1558-1497, Vol: 59, Page: 80-90

Publication Year:
2017
Usage 33
Abstract Views 32
Link-outs 1
Captures 92
Readers 91
Exports-Saves 1
Mentions 26
News Mentions 16
Blog Mentions 10
Social Media 100
Tweets 100
Citations 4
Citation Indexes 4
PMID:
28756942
DOI:
10.1016/j.neurobiolaging.2017.06.027
Author(s):
Mathotaarachchi, Sulantha; Pascoal, Tharick A; Shin, Monica; Benedet, Andrea L; Kang, Min Su; Beaudry, Thomas; Fonov, Vladimir S; Gauthier, Serge; Rosa-Neto, Pedro; Alzheimer's Disease Neuroimaging Initiative
Publisher(s):
Elsevier BV
Tags:
Neuroscience; Biochemistry, Genetics and Molecular Biology; Medicine
Most Recent Tweet View All Tweets
Most Recent Blog Mention
Most Recent News Mention
article description
Identifying individuals destined to develop Alzheimer's dementia within time frames acceptable for clinical trials constitutes an important challenge to design studies to test emerging disease-modifying therapies. Although amyloid-β protein is the core pathologic feature of Alzheimer's disease, biomarkers of neuronal degeneration are the only ones believed to provide satisfactory predictions of clinical progression within short time frames. Here, we propose a machine learning-based probabilistic method designed to assess the progression to dementia within 24 months, based on the regional information from a single amyloid positron emission tomography scan. Importantly, the proposed method was designed to overcome the inherent adverse imbalance proportions between stable and progressive mild cognitive impairment individuals within a short observation period. The novel algorithm obtained an accuracy of 84% and an under-receiver operating characteristic curve of 0.91, outperforming the existing algorithms using the same biomarker measures and previous studies using multiple biomarker modalities. With its high accuracy, this algorithm has immediate applications for population enrichment in clinical trials designed to test disease-modifying therapies aiming to mitigate the progression to Alzheimer's disease dementia.